Division of Discovery Research, Kissei Pharmaceutical Co., Ltd.,
Nagano (M.M., Y.T., K.H., M.A., Y.A.); and Department of Urology, Kinki
University School of Medicine, Osaka, Japan (Y.-C.P., N.O., T.S., T.K.)
 |
Introduction |
Complete
or partial ureteral obstruction can be caused by urinary calculi and
can lead to edema, inflammation, and infection of the upper urinary
tract, as well as to changes in ureteral functions (Biancani et al.,
1976
; Crowley et al., 1990
). The resulting increase in
intraluminal pressure in the upper urinary tract is the major cause of
ureteral colic (Michaelson, 1974
; Moriel et al., 1990
). Previous
clinical studies have shown that antispasmodics (e.g., anticholinergic
agents, calcium antagonists, or papaverine) are effective for the
relief of ureteral colic, and possibly for the promotion of stone
passage (Ross et al., 1967
; Jönsson et al., 1987
; Borghi et al.,
1994
). However, a relaxant with more relative ureteral smooth muscle
specificity compared with the cardiovascular system would result in
potential clinical benefits.
The autonomic nervous system is known to play an important role in
modulation of ureteral motility (Schulman, 1974
; Morita et al., 1987
),
but the functions of the parasympathetic supply to the ureter have not
been well defined. Muscarinic receptors and cholinergic nerves can be
demonstrated in mammalian ureters, with the innervation being rich in
the intravesical ureter but scarce in the proximal ureter (del Tacca,
1978
; Hernández et al., 1993
), and the excitatory effects of
cholinergic agonists are believed to result from both a direct
muscarinic stimulation (Hernández et al., 1993
) and an indirect
release of catecholamines (Rose and Gillenwater, 1974
). In the case of
the sympathetic nervous system, adrenoceptors (ARs) and adrenergic
nerves have been demonstrated in mammalian ureters (Latifpour et al.,
1990
; Edyvane et al., 1994
), and in vitro and in vivo studies have both
shown that
-AR agonists stimulate, whereas
-AR agonists inhibit,
ureteral motility (Deane, 1967
; Malin et al., 1970
; Weiss et al., 1978
;
Morita et al., 1987
). In the rabbit ureter, isoproterenol increases
adenylate cyclase activity and the cAMP level, and these are reduced by propranolol (Weiss et al., 1977
).
Recently, Tomiyama et al. (1998)
indicated that there are
significant species differences in the
-AR subtypes mediating the relaxation of ureteral smooth muscle:
1-ARs in
the rat,
2-ARs in the rabbit, and
3-ARs in the dog. In the case of the isolated dog ureter,
(R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243, a
3-AR agonist) and isoproterenol
were both effective at relaxing the KCl-induced contraction than was
either dobutamine (a
1-AR agonist) or
procaterol (a
2-AR agonist). Park et al. (1997)
showed the coexistence of
3-ARs with
2-ARs in the human ureter; CGP-12177 (a
3-AR agonist), procaterol, and isoproterenol were more effective at relaxing either the spontaneous rhythmic contraction or the KCl-induced contraction than was dobutamine in the
isolated human ureter. In addition, like in the human ureter,
3-ARs are present in the human detrusor, and
the relaxation induced by adrenergic stimulation is mediated mainly by
3-ARs (Igawa et al., 1999
).
In the present study, we attempted to evaluate the effects of a
selective
3-AR agonist on obstructive
dysfunctions in the upper urinary tract using an acute ureteral
obstruction model in the anesthetized dog. To this end, we compared the
effects of isoproterenol (a nonselective
-AR agonist), CL 316243 (a
3-AR agonist; Largis et al., 1994
), and
butylscopolamine (an anticholinergic agent) on the elevated
intraluminal ureteral pressure (UP) and impeded urine flow in the
obstructed ureter; we also compared the hemodynamic effects of these
drugs. In addition, we observed obstructive changes in the kidney after
the administration of isoproterenol, CL 316243, or butylscopolamine.
 |
Materials and Methods |
Animals.
The animal experiments in this study were conducted
in accordance with guidelines issued by the Kissei Pharmaceutical Co. Ltd. Animal Care and Use Committee. Adult beagle dogs (Nihon Nosan Kogyo, Yokohama, Japan) were housed individually with free access to
tap water and commercial food pellets (CD-5; Nihon Clea, Osaka, Japan).
The room temperature and humidity were ~ 23°C and ~55%, respectively, and a 12-h light/dark cycle was maintained.
Acute Ureteral Obstruction in Anesthetized Dogs.
Dogs of
either sex, weighing 8.0 to 14.0 kg, were anesthetized with sodium
pentobarbital (30 mg/kg i.v.) and immediately intubated. Artificial
ventilation with room air was maintained using a volume-limited ventilator (SN-480-3; Shinano Seisakusyo, Tokyo, Japan: 20 ml/kg, 15 strokes/min). The dog was placed on a heating pad to minimize heat
loss. Figure 1 shows a schematic
representation of the experimental model. After an abdominal midline
incision, the left ureter was identified. The left kidney was minimally
dissected free from adjacent tissues, and a small nephrotomy was made
on the convex border. A catheter was inserted using a indwelling needle
(23 gauge × 200 mm; Hakko, Tokyo, Japan) into the upper ureter via the
renal pelvis, with the tip being placed ~5 cm above the
ureterovesical junction. The other end of the catheter was connected to
a pressure transducer (P23XL; Gould, Valley View, OH) for the
measurement of UP. The distal portion of the left ureter was isolated
at a site within 1 cm of the ureterovesicular junction, and a small ureterotomy was made. A balloon catheter (Fogarty 2F balloon
embolectomy catheter; Baxter, Irvine, CA) filled with water was
advanced up into the lower ureter, so the distance between the balloon
and the tip of the catheter used for UP recording was ~2 cm. Another catheter (PE 50; Becton Dickinson, Parsippany, NJ) was inserted in
parallel with the balloon catheter, with the tip being placed just
proximal to the bladder side of the balloon for the measurement of the
urine flow before ureteral obstruction (UF). The ureter was ligated
with a thread distally to prevent passage of urine from the obstructed
ureter into the bladder, and another thread was tightened around the
ureter with two catheters. We ensured there was no leakage from the
ureterotomized site by infusing a small amount of physiological saline
into the ureter via the catheter used for UP recording. After ureteral
obstruction, we noted the magnitude of the urine flow leaking around
the balloon and draining to below the obstructed site [urine outflow
(UFo)]. The right femoral artery was cannulated, and arterial blood
pressure (BP) was recorded via a pressure transducer (P23XL; Gould).
Heart rate (HR) was obtained from the arterial pulse wave by means of a
cardiotachometer (AT-601G; Nihon Kohden, Tokyo, Japan). UP, BP, and HR
were all recorded on a thermowriting rectigraph (WS-681G; Nihon
Kohden). Throughout the experiment, physiological saline (10 ml/kg/h)
was infused intravenously to ensure a stable urine flow. Anesthesia was
maintained with an infusion of sodium pentobarbital (3-5 mg/kg/h
i.v.).
Experimental Protocol.
After a rest period (~120 min) to
allow stabilization of UP, UF, and hemodynamic parameters, the balloon
was gradually inflated with water using an infusion pump (KN-201;
Natsume Seisakusyo, Tokyo, Japan). Complete ureteral obstruction was
considered to have been achieved when UF stopped. The volume of water
infused into the balloon was stable in each dog (~20 µl). When UP
had risen and barely changed for more than 10 min, it was considered to
be the plateau UP, and vehicle or one dose of one drug was injected
i.v. The dogs were divided into seven groups depending on whether they
received physiological saline (vehicle, n = 6); isoproterenol at 1 µg/kg (n = 4) or 10 µg/kg
(n = 5); CL 316243 at 0.1 µg/kg (n = 4), 0.3 µg/kg (n = 4), or 1 µg/kg
(n = 4); or butylscopolamine at 1000 µg/kg
(n = 4). UP, BP, and HR were recorded for 120 min after
drug administration because elevated UP sometimes decreased gradually
after that time without development of UFo in vehicle-treated dogs (in
a preliminary experiment). UF was measured for the 20 min immediately
before ureteral obstruction, and UFo was measured for one 20-min period
just before and six consecutive 20-min periods after drug administration.
Histological Determination.
Dogs were sacrificed with the
administration of an excess dose of sodium pentobarbital 120 min after
drug administration. The left and right kidneys were immediately
excised and weighed and then immersed in buffered 10% formalin. After
fixation, the kidneys were embedded in paraffin wax and cut into
sections 3 to 4 µm thick. The sections were stained with H&E.
Histopathological findings were classified into four grades: no
remarkable change (0), slight change (1), moderate change (2), and
severe change (3). The grading of histopathological findings was
performed by an observer who was blind to the treatment group from
which the tissue was obtained. Both the rate and the degree of tubules
with dilated lumen and flatted epithelium existing in a section were completely judged.
Drugs.
Isoproterenol [(
)-isoproterenol bitartrate] and
butylscopolamine [(
)-scopolamine N-butyl bromide] were
obtained from Sigma Chemical Co. (St. Louis, MO). Sodium pentobarbital
was obtained from Dainippon Pharmaceutical Co. Ltd. (Osaka, Japan).
Sodium heparin was obtained from Marion Merrell Dow Co. Ltd. (Tokyo, Japan). CL 316243 was synthesized by Kissei Pharmaceutical Co. Ltd.
(Hotaka, Japan). All drugs were dissolved in physiological saline.
Statistical Analysis.
The data are expressed as mean ± S.E. A one-way ANOVA was used for the statistical analysis of multiple
comparisons within each group. When a significant difference was
detected by the one-way ANOVA, the data were further analyzed with
Dunnett's test. A Student's t test for unpaired data was
used when comparisons were made between two groups. The difference
between UFo values was analyzed with Wilcoxon's sign rank test because
the data were not normally distributed. A value of P < .05 was considered to indicate statistical significance.
 |
Results |
Effects of Isoproterenol, CL 316243, and Butylscopolamine on UP,
BP, and HR.
Before ureteral obstruction, rhythmic UP waves
associated with each ureteral peristalsis were observed in anesthetized
dogs. In terms of the baseline UP, mean blood pressure (MBP), and HR, there were no significant differences among the vehicle-, isoproterenol (1 and 10 µg/kg i.v.)-, CL 316243 (0.1, 0.3, and 1 µg/kg i.v.)-, and butylscopolamine (1000 µg/kg i.v.)-treated groups (Table
1). Within 5 min of complete ureteral
obstruction, both the peristaltic rate and the peak UP increased
transiently (Fig. 2). The baseline UP
then reached a plateau, and the ureteral peristalsis disappeared. The
plateau UP was 52.5 ± 6.9 mm Hg (n = 6) and the
time required to reach the plateau after ureteral obstruction was
86.2 ± 4.8 min (n = 6) in vehicle-treated dogs.
Neither the UP, MBP, and HR values recorded before drug administration
nor the time between ureteral obstruction and drug administration was
significantly different among the seven treatment groups (Table 1). In
the vehicle-treated group, UP, like MBP and HR, barely changed for 120 min after its administration (see Figs. 4-6).
View this table:
[in this window]
[in a new window]
|
TABLE 1
UP, MBP, and HR before ureteral obstruction and before drug
administration (but after initiation of ureteral obstruction), together
with time between ureteral obstruction and drug administration
Values are mean ± S.E.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
A typical tracing of UP after complete ureteral
obstruction produced by inflation of the balloon catheter in an
anesthetized dog.
|
|
Figure 3 shows typical tracings of the
effects of isoproterenol (10 µg/kg i.v.; Fig. 3A), CL 316243 (1 µg/kg i.v.; Fig. 3B), and butylscopolamine (1000 µg/kg i.v.; Fig.
3C) on UP, BP, and HR. Intravenous administration of isoproterenol at
dosages of 1 and 10 µg/kg induced a dose-dependent decrease in the
elevated UP (Fig. 4). The reduction in UP
was maintained from 2 to 5 min and from 2 to 60 min, respectively, in 1 and 10 µg/kg isoproterenol-treated dogs. The maximum effect was seen
with 10 µg/kg at 2 min, with UP being decreased by 74.1 ± 5.3%
(n = 5) at this time. Isoproterenol (1 and 10 µg/kg)
transiently but significantly decreased MBP and increased HR (Fig. 4).
In 10 µg/kg isoproterenol-treated dogs, MBP decreased by 51.7 ± 8.0% (n = 5) and HR increased by 57.9 ± 7.3%
(n = 5) at 2 min.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Typical tracings of the effects of isoproterenol (10 µg/kg i.v.; A), CL 316243 (1 µg/kg i.v.; B), and butylscopolamine
(1000 µg/kg i.v.; C) on UP, BP, and HR in anesthetized dogs. Arrow,
point of the injection of each drug.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of isoproterenol on UP, BP, and HR in
anesthetized dogs. , vehicle i.v. (n = 6). ,
isoproterenol, 1 µg/kg i.v. (n = 4). ,
isoproterenol, 10 µg/kg i.v. (n = 5). Vehicle or
isoproterenol was injected at time 0. *P < .05, significant difference from vehicle-treated controls.
|
|
UP was not affected by 0.1 µg/kg CL 316243, but it showed a
continuous and dose-dependent decrease with 0.3 and 1 µg/kg CL 316243 from 5 to 120 min after its administration (Fig.
5). In 0.3 µg/kg CL 316243-treated
dogs, UP was decreased by 54.3 ± 6.5% (n = 4) at
20 min; it then gradually recovered, only to fall again from 60 to 120 min. In 1 µg/kg CL 316243-treated dogs, UP was decreased by 77.2 ± 6.1% (n = 4) at 20 min, and this decrease was
sustained for an additional 100 min; as a result, UP stayed between
8.2 ± 4.0 mm Hg (n = 4) and 13.0 ± 3.0 mm
Hg (n = 4) from 20 to 120 min. CL 316243 at doses of
0.3 and 1 µg/kg induced a gradual decrease in MBP and increase in HR
(Fig. 5). The maximum effects were achieved with 1 µg/kg at 30 min,
with MBP being decreased by 12.7 ± 4.0% (n = 4)
and HR increased by 28.2 ± 5.1% (n = 4) at this
time.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of CL 316243 on UP, BP, and HR in
anesthetized dogs. , vehicle i.v. (n = 6). ,
CL 316243, 0.1 µg/kg i.v. (n = 4). , CL
316243, 0.3 µg/kg i.v. (n = 4). , CL 316243, 1 µg/kg i.v. (n = 4). Vehicle or CL 316243 was
injected at time 0. *P < .05, significant
difference from vehicle-treated controls.
|
|
Butylscopolamine at a dose of 1000 µg/kg transiently decreased UP
within 10 min of administration in three of the four animals (by 13.5, 36.4, and 42.7% in each dog) but increased UP in a remaining animal
(by 20.9%), failing to show statistically significant effects on UP
(Fig. 6). Both MBP and HR were decreased
by 29.6 ± 3.4% (n = 4) and 18.3 ± 2.8%
(n = 4) at 2 min, respectively (Fig. 6). Atrioventricular block was transiently observed in two of the four
animals within 5 min of administration.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of butylscopolamine on UP, BP, and HR in
anesthetized dogs. , vehicle i.v. (n = 6). ,
butylscopolamine, 1000 µg/kg i.v. (n = 4).
Vehicle or butylscopolamine was injected at time 0. *P < .05, significant difference from
vehicle-treated controls.
|
|
Effects of Isoproterenol, CL 316243, and Butylscopolamine on
UFo.
Figure 7 shows the effects of
isoproterenol, CL 316243, and butylscopolamine on UFo from the
obstructed ureter in anesthetized dogs. Before ureteral obstruction, UF
values were not significantly different among the vehicle-,
isoproterenol (1 and 10 µg/kg i.v.)-, CL 316243 (0.1, 0.3, and 1 µg/kg i.v.)-, and butylscopolamine (1000 µg/kg i.v.)-treated
groups. After ureteral obstruction, UFo was not observed for 120 min in
vehicle-treated dogs (with the exception of a small UFo from 80 to 120 min in one of the six animals). We also measured the urine flow from
the right (nonobstructed) ureter in the same dogs; it did not change
significantly for 120 min (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of isoproterenol, CL 316243, and
butylscopolamine on UFo in anesthetized dogs. UFo was measured every 20 min after drug administration. A, vehicle, i.v. (n = 6). B, isoproterenol, 1 µg/kg i.v. (n = 4). C,
isoproterenol, 10 µg/kg i.v. (n = 5). D, CL
316243, 0.1 µg/kg i.v. (n = 4). E, CL 316243, 0.3 µg/kg i.v. (n = 4). F, CL 316243, 1 µg/kg i.v.
(n = 4). G, butylscopolamine, 1000 µg/kg i.v.
(n = 4). Vehicle, isoproterenol, CL 316243, or
butylscopolamine was injected at time 0. *P < .05, significant difference from vehicle-treated controls. First column in
each panel shows UF for the 20 min before ureteral obstruction (a); UFo
is expressed as a percentage of UF in each dog.
|
|
In almost all dogs in the isoproterenol- and CL 316243-treated groups,
the first trace of UFo was observed during the recovery from the
maximum reduction in UP induced by the drugs, and a continuous UFo
developed thereafter, whereas the distribution was rather skewed in
each dog. Isoproterenol at a dose of 10 µg/kg significantly increased
UFo from 40 to 120 min; UFo was present in each of the five animals
from 80 to 120 min. UFo was increased from 40 to 80 min by 0.3 µg/kg
CL 316243 and from 40 to 120 min by 1 µg/kg CL 316243. UFo was
present in each of the four animals from 60 to 120 min in 1 µg/kg CL
316243-treated dogs. In contrast, butylscopolamine (1000 µg/kg) did
not increase UFo significantly. UFo was not observed for 120 min in two
of the four animals.
Effects of Isoproterenol, CL 316243, and Butylscopolamine on
Kidney.
Table 2 shows the left
(obstructed) kidney weight (LKW), right (nonobstructed) kidney weight
(RKW), and the LKW/RKW ratio 120 min after the administration of
vehicle, isoproterenol (1 and 10 µg/kg i.v.), CL 316243 (0.1, 0.3, and 1 µg/kg i.v.), and butylscopolamine (1000 µg/kg i.v.). In
addition, we weighed both kidneys in normal (without ureteral
obstruction or drug administration) dogs. LKW/RKW was significantly
greater in vehicle-treated dogs than in normal dogs. CL 316243 at doses
of 0.3 and 1 µg/kg significantly and dose dependently suppressed the
increase in LKW/RKW to an extent close to that in normal dogs and also
tended to decrease LKW, indicating that CL 316243 attenuated the
increase in LKW seen after ureteral obstruction.
View this table:
[in this window]
[in a new window]
|
TABLE 2
Effects of isoproterenol, CL 316243, and butylscopolamine on LKW, RKW,
and LKW/RKW
Values are mean ± S.E.
|
|
Under the light microscope, a dilatation of renal tubules could be seen
in the left kidney (Fig. 8B) but not in
the right kidney (Fig. 8A) of vehicle-treated dogs. Although such
changes were also observed in the obstructed kidneys in all dogs, we
did not find severe (grade 3) dilatation of tubules in either 10 µg/kg isoproterenol- or 1 µg/kg CL 316243-treated dogs, but we did
in butylscopolamine-treated dogs (Table
3, Fig. 8, C and D).

View larger version (140K):
[in this window]
[in a new window]
|
Fig. 8.
Typical light microscope images of renal tubules. A,
right (nonobstructed) kidney from a vehicle-treated dog;
histopathological grade 0. B, left (obstructed) kidney from a
vehicle-treated dog; histopathological grade 3. C, left kidney from a
10 µg/kg isoproterenol-treated dog; histopathological grade 1. D,
left kidney from a 1 µg/kg CL 316243-treated dog; histopathological
grade 1. H&E stain: original magnification 50×.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3
Effects of isoproterenol, CL 316243, and butylscopolamine on the
ureteral obstruction-induced dilatation of tubules in the left kidney
Histopathological grade 0, no remarkable change; 1, slight change; 2, moderate change; and 3, severe change.
|
|
 |
Discussion |
Acute Ureteral Obstruction in Dogs.
Acute ureteral obstruction
increases the intraluminal pressure in the upper urinary tract, and the
elevated UP is responsible for inducing changes in both ureteral
functions (Biancani et al., 1976
; Crowley et al., 1990
) and renal
hemodynamics (Moody et al., 1975
). In the present study, we achieved
acute ureteral obstruction in dogs through the inflation of an
intraluminal balloon catheter to simulate the effects of an
incarcerated calculus on ureteral functions; the technique we used
involving minor modifications of previously reported methods (Stower et
al., 1986
; Crowley et al., 1990
). UP rose gradually and reached a
plateau at 52.5 mm Hg within 86.2 min of ureteral obstruction and then
showed no decline for an additional 120 min in vehicle-treated dogs
(Table 1, Figs. 4-6). This time course is consistent with previous
observations in dogs with a complete ureteral obstruction (Darracott
Vaughan et al., 1971
; Moody et al., 1975
). Thus, our model mimicked
quite closely the clinical situation in which obstructive dysfunctions result from the presence of incarcerated calculi, including elevated intraluminal pressure and stagnated urine in the upper urinary tract.
In addition to our measurements of UP, we observed a resumption in
urine flow after its interruption by the balloon (UFo), obstructive changes in the kidney, and hemodynamic parameters. By using this model
of acute ureteral obstruction in dogs, we could study the effects of
-adrenergic stimulation on ureteral, renal, and cardiovascular functions.
Effects on UP.
Previous in vitro and in vivo studies have
demonstrated that
-adrenergic stimulation inhibits ureteral
motility. Isoproterenol produces relaxation of isolated ureters in a
number of species (Malin et al., 1970
; Weiss et al., 1978
; Morita et
al., 1987
; Tomiyama et al., 1998
), whereas it decreases both ureteral
peristalsis and UP in anesthetized dogs (Rose and Gillenwater, 1974
;
Mayo and Halbert, 1981
; Morita et al., 1987
). In the present study, as
in previous in vivo studies, isoproterenol (1 and 10 µg/kg i.v.)
decreased the elevated UP seen after acute ureteral obstruction (Fig.
4), indicating that relaxation of ureteral smooth muscle by
-adrenergic stimulation actually does reduce the intraluminal pressure in the upper urinary tract. It has recently become clear that
there are significant species differences in the functional
-AR
subtypes mediating relaxation of the ureter:
1-ARs in the rat,
2-ARs in the rabbit,
3-ARs in the dog, and
2-/
3-ARs in the human
(Park et al., 1997
; Tomiyama et al., 1998
). In the present in vivo
study, the specific contribution of
3-ARs to
the relaxation of the dog ureter was confirmed; CL 316243 (0.3 and 1 µg/kg i.v.) produced an evident decrease in UP with relative smaller
hemodynamic effects (mediated mainly by
1- and
2-ARs) than with isoproterenol (Fig. 5). It is
therefore suggested that the selective adrenergic stimulation of
ureteral
-ARs may prove to be useful for relieving the ureteral
colic that follows ureteral obstruction. Furthermore, it is also
possible that the relaxation of ureteral smooth muscle by
-adrenergic stimulation would affect the mechanical factors relating
to the movement of intraluminal calculi down the ureter. Indeed, a
decrease in friction between the calculus and the ureteral mucosa as a
result of relaxation at the obstructed site (decrease in ureteral wall
tension) is considered to be one of the factors promoting stone passage
(Holmlund, 1968
; Weiss, 1997
).
Effects on UFo.
Based on the observation that both
isoproterenol (10 µg/kg i.v.) and CL 316243 (0.3 and 1 µg/kg i.v.)
significantly increased UFo from the obstructed ureter (Fig. 7), it
seems that stagnated urine above the obstructed site could leak around
the balloon and drain to below the obstructed site due to a
drug-induced relaxation of ureteral smooth muscle. In this model of
acute ureteral obstruction, a significant increase in UFo was seen 40 min after drug administration (i.e., some time after the maximum
reduction in UP induced by isoproterenol or CL 316243). Similarly, in 1 µg/kg CL 316243-treated dogs, in which UP was decreased by 77.2% at
20 min with no recovery for an additional 100 min, UFo was rather less
than that in 0.3 µg/kg CL 316243-treated dogs, in which UP was
decreased by 54.3% at 20 min followed by a gradual recovery. Although
it is difficult to explain the lack of a strict correlation between the
reduction in UP and the level of UFo with the data obtained in the
present study, it is likely that the leakage of urine around the
balloon depends both on the hydrostatic pressure above the obstructed site and the relaxation at the obstructed site itself. Furthermore, other effects of
-adrenergic stimulation could possibly modify UFo,
such as a decrease in ureteral peristalsis or an inhibition of urine
bolus formation (Mayo and Halbert, 1981
; Morita et al., 1987
). On the
basis of these results, it is speculated that relaxation of ureteral
muscle by
-adrenergic stimulation may promote urine flow around
incarcerated calculi; by decreasing ureteral wall tension, there may be
decreased force of coaptation between the point of obstruction and the
ureteral wall, which may actually decrease the pressure gradient across
the obstructed site. Such a resumption in urine flow would contribute
to a sustained reduction in UP and could possibly promote stone
passage, although further experimental studies, including the
development of new ureteral obstruction models using an artificial
calculus, are needed to clarify the effects of
-adrenergic
stimulation on urine flow and stone passage. In addition, when taken
together with the fact that UFo developed variably in each preparation
after drug administration, we must consider the existence of
uncontrolled/uncontrollable renal and prerenal factors affecting UFo
and UP (e.g., an extravasation of urine at calices, a hydration status,
or an osmotic diuresis) in this model of acute ureteral obstruction in dogs.
Effects on Kidney.
The anatomic changes occurring in the upper
urinary tract with obstruction have been investigated experimentally in
rabbits; hydronephrosis is known to develop as early as 1 day after
ureteral obstruction in association with an increase in kidney weight, with the tubules initially undergoing dilatation of the lumen with
flattening of the epithelium (Sheehan and Davis, 1959
). In the present
study, we were surprised to find that we could observe weight gain and
dilatation of tubules in the obstructed kidney only ~210 min after
ureteral obstruction in our acute preparation in dogs. CL 316243 (0.3 and 1 µg/kg i.v.) significantly suppressed the increase in LKW/RKW
(Table 2), and the histopathological findings in the obstructed kidney
of either isoproterenol (10 µg/kg i.v.)- or CL 316243 (1 µg/kg
i.v.)-treated dogs were, if anything, less severe than those of
vehicle-treated dogs (Table 3, Fig. 8). It is likely that these effects
were due both to a sustained decrease in intraluminal pressure and the
resumption in urine flow in the upper urinary tract after the
administration of isoproterenol or CL 316243. On the basis of these
results, it is possible that a secondary effect of
-adrenergic
stimulation would be an attenuation of the early development of renal
edema that follows ureteral obstruction, although further chronic
studies are required to substantiate this idea.
Hemodynamic Effects.
Previous observations in conscious dogs
have shown that the positive chronotropic effect of
3-AR agonists is attributable to a
baroreceptor-mediated reflex triggered by the fall in BP resulting from
their direct vasodilator action (Tavernier et al., 1992
; Shen et al.,
1994
). In the present study, isoproterenol at a dose of 10 µg/kg,
which decreased UP by 74.1%, maximally reduced MBP by 51.7% and
increased HR by 57.9% (2 min after its administration; Fig. 4),
whereas CL 316243 at a dose of 1 µg/kg, which decreased UP by a
similar extent (75.8%), maximally reduced MBP by only 12.7% and
increased HR by 28.2% (30 min after its administration; Fig. 5). These
results demonstrate that CL 316243 gradually decreases UP with a
relatively smaller hypotensive effect than isoproterenol. CL 316243 shows a >10,000-fold selectivity for
3-ARs
compared with both
1- and
2-ARs (Largis et al., 1994
) and a slow
relaxing kinetic in the isolated rat colon (Kaumann and Molenaar,
1996
). It is therefore suggested that in dogs, the CL 316243-induced
reduction in UP may be mainly mediated via adrenergic stimulation of
ureteral
3-ARs and bears little dependence on its effect on BP.
Conclusion.
We have demonstrated that the relaxation of
ureteral smooth muscle by CL 316243, a selective
3-AR agonist, decreases the elevated UP and
resumes urine flow in the acutely obstructed ureter in dogs. These
findings are consistent with the idea that selective adrenergic
stimulation of ureteral
-ARs may prove to be useful for relieving
ureteral colic and promoting stone passage in patients with
urolithiasis. In the human ureter, the relaxation induced by adrenergic
stimulation is mediated by both
2- and
3-ARs (Park et al., 1997
). Because
-ARs are
widely distributed in the cardiovascular system, we believe that a
specific agonist for human ureteral
-ARs with comparatively weak
hemodynamic effects would be extremely useful for the drug treatment of
urolithiasis; additional acute and chronic studies are needed to
confirm this concept.
We express their particular thanks to Dr. Takeshi Kitamura
(Kissei Pharmaceutical Co., Ltd.) for technical assistance.
Accepted for publication September 10, 1999.
Received for publication July 1, 1999.
AR, adrenoceptor;
BP, blood pressure;
HR, heart
rate;
LKW, left kidney weight;
MBP, mean blood pressure;
RKW, right
kidney weight;
UF, urine flow before ureteral obstruction;
UFo, urine
outflow;
UP, ureteral pressure.